Aims: In order to clarify the antinephritic mechanisms of saireito, the glucocorticoid receptor agonistic effect of saireito was evaluated in adrenalectomized rats with anti-glomerular basement membrane (anti-GBM) nephritis.Methods: Rats with anti-GBM nephritis were subjected to adrenalectomy to exclude the effects of endogenous steroid hormones to investigate effects of saireito on the nephritis. The suppressive effects of saireito and saikosaponin D on the production of cytokines were investigated in vitro andin vivo. Results: Administration of saireito or saikosaponin D significantly suppressed the increase of urinary protein excretion and histopathological changes in adrenalectomized nephritic rats. Coadministration of saireito or saikosaponin D and RU-38486, a glucocorticoid receptor antagonist, did not suppress the increase of urinary protein excretion. Saikosaponin D inhibited the glucocorticoid receptor binding of [3H]dexamethasone in anin vitro assay (IC50 ratio 5.8 µmol/l). The IC50 values of saikosaponin D for the release of IL-2 and IL-10 were 13.4 and 12.3 µmol/l, respectively. Administration of saireito and saikosaponin D prevented an increase in IL-2 levels in the renal cortex of anti-GBM nephritic rats. Conclusion: These results suggest that the antinephritic effects of saireito may be partly attributable to an agonistic action on the glucocorticoid receptor by saikosaponin D, a component of saireito.

1.
Marumoto M, Maeda T, Kato M, Hayashi E: Anti-inflammatory action of shosaiko-toh (in Japanese). Proc Symp Wakanyaku 1983;16:153–157.
2.
Senaga R, Kawashima S: Clinical influences of sairei-to (Chai-Ling-Tang) on renal disease in children (in Japanese). J Med Pharm Soc Wakanyaku 1986;3:45–50.
3.
Kimura K, Nanba S, Tojo A, Matsuoka H, Sugimoto T: Effects of sairei-to on the relapse of steroid-dependent nephritic syndrome. Am J Chin Med 1990;18:45–50.
4.
Yoshikawa N, Ito M, Takekoshi Y, Honda M, Awazu M, Iijima K, Nakamura H, Seino Y, Takeda N, Hattori S, Matsuda I: Standard versus long-term prednisolone with sairei-to for initial therapy in childhood steroid-responsive nephrotic syndrome: a prospective controlled study (in Japanese). Nippon Jinzo Gakkai Shi 1998;40:587–590.
5.
Hiai S, Yokoyama H, Nagasawa T, Oura H: Stimulation of the pituitary axis by saikosaponin of Bupleuri Radix. Chem Pharm Bull (Tokyo) 1981;29:495–499.
6.
Hattori T, Maruyama H, Nishimura H, Nakai Y, Sakakibara I, Kase Y, Takeda S: Effects of saireito, a Japanese herbal medicine, on edema via antagonistic actions against aldosterone in anti-GBM nephritic rats. Clin Exp Nephrol 2006;10:13–18.
7.
Taniguchi H, Nagamatsu T, Kojima R, Ito M, Suzuki Y: Marked antinephritic action and less adverse effects of methylprednisolone suleptanate by intermittent administration in rats. Jpn J Pharmacol 1994;64:79–88.
8.
Takashima K, Syukuwa S, Iwanaga N, Sakata H, Yasumori R, Tadokoro M, Kohara S, Tanaka T, Matsuo S, Muraya Y, et al: Anti-glomerular basement membrane antibody-mediated glomerulonephritis remarkably improved by pulse therapy with methylprednisolone, plasmapheresis and continuous heparin infusion (in Japanese). Nippon Jinzo Gakkai Shi 1989;31:1197–1204.
9.
Bolton WK, Sturgill BC: Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 1989;9:368–375.
10.
Hattori T, Suzuki Y: Studies on antinephritic effects of Japanese kampo medicine in rats. 3. Effects of sairei-to on accelerated passive Heymann nephritis in rats (in Japanese). J Med Pharm Soc Wakanyaku 1989;6:108–114.
11.
Hattori T, Nagamatsu T, Suzuki Y: Studies on antinephritic effects of Japanese kampo medicine in rats. 1. Effects of sairei-to on anti-GBM antibody nephritis in rats (in Japanese). J Med Pharm Soc Wakanyaku 1988;5:27–33.
12.
Shigematsu H: Masugi nephrotoxic nephritis: animal models of kidney diseases (in Japanese). Kidney Dial 1991;31:202–206.
13.
Hattori T, Nagamatsu T, Ito M, Suzuki Y: Contribution of ED-1- and CD-8-positive cells to the development of crescentic-type anti-GBM nephritis in rats. Jinzo Gakkai Shi 1994;36:1228–1239.
14.
Green PK, Wilkinson CW, Woods SC: Intraventricular corticosterone increases the rate of body weight gain in underweight adrenalectomized rats. Endocrinology 1992;130:269–275.
15.
Mujais SK, Chekal MA, Jones WJ, Hayslett JP, Katz AI: Regulation of renal Na-K-ATPase in the rat. Role of the natural mineralo- and glucocorticoid hormones. J Clin Invest 1984;73:13–19.
16.
Cidlowski JA, Cidlowski NB: Regulation of glucocorticoid receptors by glucocorticoids in cultured HeLa S3 cells. Endocrinology 1981;109:1975–1982.
17.
Welker P, Lippert U, Nürnberg W, Krüger-Krasagakes S, Möller A, Czarnetzki B: Glucocorticoid-induced modulation of cytokine secretion from normal and leukemic human myelomonocytic cells. Int Arch Allergy Immunol 1996;109:110–115.
18.
Tsuchiyama Y, Wada J, Zhang H, Morita Y, Hiragushi K, Hida K, Shikata K, Yamamura M, Kanwar YS, Makino H: Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats. Kidney Int 2000;58:1941–1952.
19.
Hattori T, Shindo S, Hisada T, Fujitsuka N, Hibino T, Terazono Y, Maruno M: Effects of Onpi-to (TJ-8117) on mesangial injury induced by anti-Thy-1 antibody (in Japanese). Nippon Yakurigaku Zasshi 1995;105:63–75.
20.
Leech M, Huang XR, Morand EF, Holdsworth SR: Endogenous glucocorticoids modulate experimental anti-glomerular basement membrane glomerulonephritis. Clin Exp Immunol 2000;119:161–168.
21.
Franchimont D, Louis E, Dewe W, Martens H, Vrindts-Gevaert Y, De Groote D, Belaiche J, Geenen V: Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell culture. Regul Pept 1998;73:59–65.
22.
Kunicka JE, Talle MA, Denhardt GH, Brown M, Prince LA, Goldstein G: Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell Immunol 1993;149:39–49.
23.
Hattori T, Furuta K, Hayashi K, Nagamatsu T, Ito M, Suzuki Y: Studies on the antinephritic effects of plant components (6): antinephritic effects and mechanisms of phellodendrine (OB-5) on crescentic-type anti- GBM nephritis in rats (2). Jpn J Pharmacol 1992;60:187–195.
24.
Hayashi K, Nagamatsu T, Ito M, Suzuki Y: Suppression of experimental crescentic-type anti-glomerular basement membrane (GBM) nephritis by FK506 (tacrolimus hydrate) in rats. Jpn J Pharmacol 1996;70:43–54.
25.
Ikezumi Y, Kanno K, Koike H, Tomita M, Uchiyama M, Shimizu F, Kawachi H: FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3. Kidney Int 2002;61:1339–1350.
26.
Li P, Gong Y, Zu N, Li Y, Wang B, Shimizu F: Therapeutic mechanism of saikosaponin-d in anti-Thy1 mAb 1-22-3-induced rat model of glomerulonephritis. Nephron Exp Nephrol 2005;101:e111–e118.
27.
Hattori T, Ito M, Suzuki Y: Studies on antinephritic effects of plant components in rats (1): effects of saikosaponins on original-type anti-GBM nephritis in rats and its mechanisms (in Japanese). Nippon Yakurigaku Zasshi 1991;97:13–21.
28.
Salant DJ, Belok S, Stilmant MM, Darby C, Couser WG: Determinants of glomerular localization of subepithelial immune deposits: effects of altered antigen to antibody ratio, steroids, vasoactive amine antagonists, and aminonucleoside of puromycin on passive Heymann nephritis in rats. Lab Invest 1979;41:89–99.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.